Cargando…

The Frequency and Clinical Significance of IDH1 Mutations in Chinese Acute Myeloid Leukemia Patients

OBJECTIVE: Mutations in the gene encoding isocitrate dehydrogenease 1 (IDH1) occur in various hematopoietic tumors including acute myeloid leukemia (AML), myeloproliferative neoplasms and myelodysplastic syndromes. IDH1 mutations are significant in both diagnosis and prognosis of these conditions. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Lixun, Gao, Li, Wang, Lili, Li, Meng, Yin, Yue, Yu, Li, Gao, Chunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869765/ https://www.ncbi.nlm.nih.gov/pubmed/24376688 http://dx.doi.org/10.1371/journal.pone.0083334

Ejemplares similares

IDH1/2 mutations in acute myeloid leukemia
por: Byun, Ja Min, et al.
Publicado: (2022)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Characteristics of Cohesin Mutation in Acute Myeloid Leukemia and Its Clinical Significance
por: Han, Caixia, et al.
Publicado: (2021)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

ABO Blood Type Incompatibility Is Not a Risk Factor of Outcomes for Acute Myeloid Leukemia (AML) Patients After Unmanipulated Haplo-Identical Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Yang, Nan, et al.
Publicado: (2019)

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
por: Sarkaria, Shawn M., et al.
Publicado: (2014)

Haploidentical, Unmanipulated Granulocyte Colony-Stimulating Factor (G-CSF)-Primed Peripheral Blood Stem Cell Transplants for Acute Myeloid Leukemia (AML) in Remission: A Single Center Experience
por: Luo, Lan, et al.
Publicado: (2019)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
por: Messina, Monica, et al.
Publicado: (2022)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
por: Daido, Yusuke, et al.
Publicado: (2023)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome
por: Kelly, Andrew D., et al.
Publicado: (2017)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique
por: Wang, Rui‐Qi, et al.
Publicado: (2020)

Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia
por: Xu, Xiaoyan, et al.
Publicado: (2023)

The frequency of NPM1 mutations in childhood acute myeloid leukemia
por: Braoudaki, Maria, et al.
Publicado: (2010)

Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis
por: Qin, Yao, et al.
Publicado: (2023)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
por: Chotirat, Sadudee, et al.
Publicado: (2012)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
por: Bhide, Aniket, et al.
Publicado: (2023)

CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population
por: Su, Long, et al.
Publicado: (2016)

Functions and clinical significance of circular RNAs in acute myeloid leukemia
por: Zhou, Min, et al.
Publicado: (2022)

Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia
por: Wang, Dandan, et al.
Publicado: (2023)

Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients
por: Grassi, Susanna, et al.
Publicado: (2020)

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies
por: Chen, Shuchen, et al.
Publicado: (2022)

Clinical significance and potential mechanism of heat shock factor 1 in acute myeloid leukemia
por: Lyu, Chunyi, et al.
Publicado: (2022)

Correction: Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia
por: Wang, Dandan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_upak0o2piadfnugr70o659m3j7